]>
IRCT20200509047373N1 IRCT 2020-05-23 Health Medicine Chemistry Company Evaluation effect of Dinvl for Covid19 infection Evaluation effects of DINVL herbal medicine on the recovery of patients with COVID - 19 2020-06-03 anticipated 60 Complete https://irct.ir/trial/48001 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In this study, patients with admission conditions were divided into two groups. In addition to the usual treatment for coronavirus infection, the intervention group received Dinvl daily for 7consecutive days, but the control group received only routine treatment for corona infection , Randomization description: In this study, the random number table method is used for randomization.The randomization unit is also the individual.To read numbers, it is also from left to right.For concealment, the method of sequentially numbered, sealed, opaque envelopes is used, Blinding description: In this study, patients, the main researcher, the physician who visits patients daily for response to the treatment and examination of symptoms, and is responsible for collecting information, and the nursing staff are kept blind to the allocation of study groups.All patients are visited daily by one of the physicians of the treatment team who is in the process of intervention.However, the follow-up of the side effects of the drug and the evaluation of the course of treatment in patients will be performed by another physician, who is also in the general study constant.This physician will monitor the condition of patients at home for up to 4 weeks after discharge and will be completely blind. 2-3 Pneumonia induced by covid19. Intervention 1: Intervention group:ُُDinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company. Intervention 2: Control group: Routine tablets is given daily for seven days. Yes - There is a plan to make this available What will be shared: All participants' data is shared after it becomes unrecognizable When: Data access starts immediately after printing the results To whom: The data in this study are only available to medical researchers Conditions: It is available for any analysis or use that aims to improve and progress in the treatment of covid19 infection Where to obtain: Contact email address:ahisseinpour3@gmail.com How to obtain: In case of requesting data for the study, the applicant must first introduce himself or herself and the relevant organization to determine the purpose of the data request and state for what purpose this data is used.After submitting the request, if the researchers of this study prove that the data of this study can advance the therapeutic goals, the information will be sent as long as the data remains confidential.This process takes two weeks. Comments:
public Ahmad Hosseinpour
No. 256, Alley 7, Peace Boulevard, Skills Square, Shiraz
Shiraz Iran (Islamic Republic of) 7177654547 +98 71 3739 7910 ahosseinpour3@gmail.com Health Medicine Chemistry Company scientific Ahmad Hosseinpour
No. 256, Alley 7, Peace Boulevard, Skills Square, Shiraz
Shiraz Iran (Islamic Republic of) 7177654547 +98 71 3739 7910 ahosseinpour3@gmail.com Health Medicine Chemistry Company Iran (Islamic Republic of) Patients up18 years old hospitalized Patient with SpO2:85-89% on room air at admission (if correct with nasal O2 maximum 6 liter/min to SpO2>=90 ) Patients with SpO2: 90-93% and RR>=30 clinical compatible patients with positive RT-PCR test or consistent HRCT to covid19 pneumonia Sign the study participation form no limit no limit Both Known sensitivity to plant compounds. Pregnant woman Lactating woman Patients with active peptic. U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group:ُُDinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company Control group: Routine tablets is given daily for seven days Time to clinical recovery. Timepoint: Control clinical signs daily until discharge from the hospital. Method of measurement: Fever control with thermometer, oxygen saturation control with pulsoximetry. 14 days readmission after discharge. Timepoint: Up to 14 days after discharge. Method of measurement: All patients will be given a contact number to notify them if they are hospitalized again. All patients will be monitored by phone weekly for up to 4 weeks after the first day they are admitted. Health Medicine Chemistry Company Approved 2020-05-09 Medical Ethics Committee of Baqiyatallah University of Medical Sciences Baqiyatallah University of Medical Sciences, Molla Sadra Street Tehran Tehran Iran (Islamic Republic of)